Get the Stockscreener App
6.925
3.28%
-0.235
Regenxbio Inc stock is traded at $6.925, with a volume of 1.21M.
It is down -3.28% in the last 24 hours and down -13.22% over the past month.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
See More
Previous Close:
$7.16
Open:
$7.14
24h Volume:
1.21M
Relative Volume:
0.80
Market Cap:
$457.14M
Revenue:
$170.44M
Net Income/Loss:
$-193.88M
P/E Ratio:
-1.8446
EPS:
-3.7541
Net Cash Flow:
$-126.38M
1W Performance:
-14.19%
1M Performance:
-13.22%
6M Performance:
-24.65%
1Y Performance:
-43.88%
1-Day Range:
$6.875
$7.18
1-Week Range:
$6.80
$8.29
52-Week Range:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
6.925 | 457.14M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Initiated | Mizuho | Outperform |
| Aug-07-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
JPMorgan reports a passive stake above 5% in REGENXBIO (RGNX). - Stock Titan
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - www.marketscreener.com
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - PR Newswire
Gene Therapy Patent Suit Against Sarepta Comes To Close - Law360
Regenxbio, Penn End Revived Sarepta Gene-Therapy Patent Fight - Bloomberg Law News
Exclusive BAC Article: REGENXBIO; BLA Submisison RGX-202 DMD Q3 2026, Topline Data Ph3 ABBV-RGX-314 Wet-AMD Q4 2026, And Catalysts (NASDAQ:RGNX) - Seeking Alpha
Mizuho Initiates Regenxbio (RGNX) Coverage with Outperform Ratin - GuruFocus
RGNX Initiates Coverage On Mizuho -- Rating Set to Outperform - GuruFocus
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call - Yahoo Finance
Full Transcript: Regenxbio Q2 2026 Earnings Call - Benzinga
Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Mizuho initiates Regenxbio stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Mizuho initiates Regenxbio stock coverage with outperform rating - Investing.com
ETFs Investing in REGENXBIO, Inc. Stocks - TradingView
Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0 - TradingView
H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data - Investing.com
REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine
Stifel reiterates Regenxbio stock rating on gene therapy data - Investing.com
Why is Regenxbio stock climbing today? - Investing.com India
Why is Regenxbio stock climbing today? - Investing.com
Regenxbio stock gains on positive gene therapy trial data - Investing.com
REGENXBIO reports three-year sura-vec Phase II results - grafa.com
Regenxbio stock gains on positive gene therapy trial data - Yahoo Finance
RGNX Looks 52.3% Undervalued on GF Value™ Despite Challenges - GuruFocus
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Singapore
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting - PR Newswire
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement - Kalkine Media
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date - TradingView
Responsive Playbooks and the RGNX Inflection - Stock Traders Daily
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a Potential 188.83% Upside in Biotech Innovation - DirectorsTalk Interviews
REGENXBIO Inc. stock steadies after Morgan Stanley conference appearance - AD HOC NEWS
Certain Warrants of REGENXBIO Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2026. - marketscreener.com
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research - Barchart.com
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
REGENXBIO to Participate in Upcoming Investor Conferences - tradingview.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances - streetwisereports.com
This REGENXBIO Insider Increased Their Holding In The Last Year - Moomoo
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director |
Aug 26 '26 |
Buy |
9.14 |
49,196 |
449,706 |
64,628 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
7.86 |
2,161 |
16,985 |
215,170 |
| Stephen J. Pakola | Officer |
Jul 01 '26 |
Proposed Sale |
11.98 |
43,206 |
517,608 |
0 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
| STEPHEN PAKOLA | Officer |
May 11 '26 |
Proposed Sale |
10.55 |
34,917 |
368,374 |
0 |
| PAKOLA STEVE | Chief Medical Officer |
May 11 '26 |
Sale |
11.02 |
15,309 |
168,705 |
232,617 |
| STEPHEN J PAKOLA | Officer |
Mar 10 '26 |
Proposed Sale |
10.38 |
5,124 |
53,187 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):